# colorectal cancer - deepseek-v4-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 3
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 46996
- Completion tokens: 20571
- Reasoning tokens: 0
- Total tokens: 67567
- API requests reported: 4
- Elapsed seconds: 93.533
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 3/5; original repeat 3; model vendor: DeepSeek

---
# Multidimensional Interpretation of Prognostic Transcriptomic Data in Colorectal Cancer

## 1. Overall Biological Interpretation

This survival analysis of 100 unique genes in colorectal tumor tissue identifies a prognostic transcriptomic landscape dominated by **mesenchymal/EMT-associated signaling, extracellular matrix remodeling, and metabolic reprogramming** as the major risk-associated themes, while the protective-associated signature is enriched for **mitochondrial oxidative metabolism, intestinal differentiation, and epithelial identity maintenance**.

The risk-associated genes (HR > 1; n = 54) include well-established drivers of aggressive colorectal cancer biology: **INHBB** (activin/inhibin signaling, HR = 1.433), **DCBLD2** (HR = 1.408), **TPM4** (HR = 1.364), **ZEB1-AS1** (EMT-associated lncRNA, HR = 1.372), **NT5E/CD73** (HR = 1.313), **MSLN** (HR = 1.313), and **AKT3** (HR = 1.318). These converge on programs of epithelial-to-mesenchymal transition, proliferation, and immune modulation.

The protective-associated genes (HR < 1; n = 46) include **CDX2** (HR = 0.748) and **CDX1** (HR = 0.781) — master regulators of intestinal differentiation — alongside multiple mitochondrial respiratory chain components (**NDUFA9**, **ATP5B**, **ATP5G1**, **COA3**, **TIMM13**) and metabolic enzymes (**CS**, **ACSS2**, **ASL**). This pattern suggests that retention of differentiated intestinal epithelial identity and oxidative metabolic function is associated with better overall survival.

**Key caveat**: This is a single-cohort prognostic analysis. External statistical validation in an independent cohort was **not performed** — pathway recurrence, literature support, and database records are contextual evidence only, not replication.

---

## 2. Core Biological Programs

### Program 1: EMT / Mesenchymal Transition and ECM Remodeling
- **Prognostic association**: Risk-associated (worse OS)
- **Major supporting genes**: ZEB1-AS1 (HR = 1.372), TPM4 (HR = 1.364), DCBLD2 (HR = 1.408), ITGBL1 (HR = 1.299), ADAMTS18 (HR = 1.263), SCEL (HR = 1.254), MAP1B (HR = 1.327), NT5E (HR = 1.313)
- **Standardized pathway**: Hallmark Epithelial Mesenchymal Transition; KEGG: ECM-receptor interaction; Reactome: Extracellular matrix organization
- **Rationale**: **ZEB1-AS1** is an antisense transcript of ZEB1, a master EMT transcription factor. **TPM4** encodes tropomyosin-4, an actin-binding protein upregulated in mesenchymal cells. **ITGBL1** (integrin beta-like 1) and **ADAMTS18** are ECM-related genes; **DCBLD2** is a transmembrane receptor associated with invasive phenotypes. **NT5E/CD73** promotes an immunosuppressive, mesenchymal-like microenvironment. The co-occurrence of an EMT master-regulator lncRNA with cytoskeletal, ECM, and adhesion-related genes collectively supports a mesenchymal transition program.
- **Evidence strength**: Moderate — multiple independent genes with coherent function; but no formal enrichment statistic was computed for this cohort. Literature support is strong for ZEB1-AS1, TPM4, and NT5E in CRC aggressiveness.

### Program 2: TGF-β / Activin Signaling
- **Prognostic association**: Risk-associated
- **Major supporting genes**: INHBB (HR = 1.433), FGF19 (HR = 1.291), AKT3 (HR = 1.318), GADD45B (HR = 1.324)
- **Standardized pathway**: KEGG: TGF-beta signaling pathway; Reactome: Signaling by TGF-beta family members
- **Rationale**: **INHBB** encodes the inhibin beta B subunit, a component of activin B, a TGF-β superfamily ligand. Recent literature (Europe PMC record 41992239) directly reports high INHBB expression in CRC is associated with poor prognosis and drives malignant phenotypes. **FGF19** and **AKT3** are downstream signaling amplifiers that can cooperate with TGF-β/activin pathways. **GADD45B** is a stress-response gene linked to MAPK/JNK signaling, often downstream of TGF-β.
- **Evidence strength**: Moderate — INHBB is the strongest single-gene signal in the cohort (HR = 1.433, FDR = 0.0011), supported by recent CRC-specific literature. However, pathway-level enrichment was not formally tested.

### Program 3: Loss of Intestinal Differentiation / Enterocyte Identity
- **Prognostic association**: Protective-associated (higher expression = better OS)
- **Major supporting genes**: CDX2 (HR = 0.748), CDX1 (HR = 0.781), LGALS4 (HR = 0.771), MYO5B (HR = 0.748), LGALS9 (HR = 0.753)
- **Standardized pathway**: GO: Intestinal epithelial cell differentiation; KEGG: Not applicable (developmental program)
- **Rationale**: **CDX2** and **CDX1** are homeobox transcription factors that specify and maintain intestinal epithelial identity. Literature (record 30631044) shows CDX2 inhibits colon cancer proliferation by suppressing Wnt/β-catenin signaling. **LGALS4** (galectin-4) is a brush-border protein of differentiated enterocytes. **MYO5B** is required for enterocyte polarity and trafficking. The coordinated protective effect of these differentiation markers suggests that **loss of differentiated intestinal identity** (a hallmark of aggressive CRC) is a key risk determinant.
- **Evidence strength**: Moderate — coherent functional group; CDX2 has strong literature support for tumor-suppressive roles in CRC. No formal enrichment computed.

### Program 4: Mitochondrial Oxidative Metabolism
- **Prognostic association**: Protective-associated
- **Major supporting genes**: NDUFA9 (HR = 0.689), ATP5B (HR = 0.748), ATP5G1 (HR = 0.747), COA3 (HR = 0.744), TIMM13 (HR = 0.751), CS (HR = 0.754), ACSS2 (HR = 0.758), OGDHL (HR = 0.686)
- **Standardized pathway**: Reactome: Respiratory electron transport / ATP synthesis by chemiosmotic coupling; KEGG: Oxidative phosphorylation; Citrate cycle (TCA cycle)
- **Rationale**: **NDUFA9** (Complex I), **ATP5B** and **ATP5G1** (Complex V), **COA3** (Complex IV assembly), **TIMM13** (mitochondrial import), **CS** (citrate synthase, TCA), **ACSS2** (acetate metabolism), and **OGDHL** (oxoglutarate dehydrogenase-like, TCA) collectively represent intact mitochondrial function. Their coordinated protective association suggests that tumors retaining oxidative metabolism rather than shifting to glycolytic/Warburg metabolism may have better prognosis.
- **Evidence strength**: Moderate — the number of independent mitochondrial genes (8+) with concordant protective direction is striking. However, this could partly reflect tumor purity or stromal content (see Limitations).

### Program 5: Immune Modulation / Immunosuppression
- **Prognostic association**: Mixed (risk: NT5E, MSLN; protective: LGALS9, TAPBPL)
- **Major supporting genes**: NT5E (HR = 1.313), MSLN (HR = 1.313), LGALS9 (HR = 0.753), TAPBPL (HR = 0.711), CCL15 (HR = 0.753)
- **Standardized pathway**: GO: Regulation of T cell migration (GO:2000404); Reactome: Immune System
- **Rationale**: **NT5E/CD73** generates immunosuppressive adenosine and is a recognized cancer immunotherapy target (literature record 36480312). **MSLN** (mesothelin) is being evaluated as a CAR-T target in CRC organoids (record 42363170). **LGALS9** (galectin-9) and **TAPBPL** (TAP-binding protein-like, involved in antigen presentation) are protective, suggesting that intact antigen presentation and immune effector function are beneficial. The mixed directions indicate that the immune program is **bidirectional**: immunosuppressive adenosine production (risk) versus intact antigen presentation (protective).
- **Evidence strength**: Moderate — supported by multiple genes with coherent but opposing directions; the directional split is biologically interpretable. No formal immune infiltration deconvolution was performed.

---

## 3. Key Genes and Interaction Modules

### 1. INHBB — Activin/TGF-β signaling hub
- **Direction**: Risk-associated; HR = 1.433, FDR = 0.0011 (strongest signal in cohort)
- **Role**: Activin B ligand; drives TGF-β superfamily signaling promoting EMT, proliferation, and stemness
- **Interactions**: Pathway co-membership with TGF-β/activin signaling (with SMADs, ACVR1B/ACVR2B receptors — not in this cohort); literature-based association with CRC aggressiveness (Europe PMC 41992239)
- **Relationship type**: Pathway co-membership; direct physical interaction with activin receptors is established in the literature but not demonstrated in this dataset

### 2. ZEB1-AS1 — EMT regulatory lncRNA
- **Direction**: Risk-associated; HR = 1.372, FDR = 0.0086
- **Role**: Antisense transcript regulating ZEB1, a master EMT transcription factor
- **Interactions**: Regulatory interaction with ZEB1 (antisense regulation, literature-supported); co-expression with EMT program genes (TPM4, DCBLD2) in this cohort
- **Relationship type**: Regulatory interaction (with ZEB1); pathway co-membership (EMT program)

### 3. CDX2 / CDX1 — Intestinal differentiation module
- **Direction**: Both protective; CDX2 HR = 0.748, CDX1 HR = 0.781
- **Role**: Master regulators of intestinal identity; CDX2 suppresses Wnt/β-catenin signaling (literature record 30631044)
- **Interactions**: CDX2 and CDX1 share homeobox DNA-binding domains and co-regulate intestinal genes; both are transcription factors
- **Relationship type**: Pathway co-membership; potential regulatory interaction (co-binding at shared enhancers) — direct physical interaction is not established

### 4. Mitochondrial oxidative metabolism module (NDUFA9, ATP5B, ATP5G1, COA3, TIMM13, CS)
- **Direction**: All protective (HR range 0.689–0.754)
- **Role**: Intact oxidative phosphorylation and TCA cycle
- **Interactions**: STRING evidence shows COA3-ILVBL and CS-ACSS2 connections; these are pathway co-members in mitochondrial metabolism
- **Relationship type**: Pathway co-membership (respiratory chain complexes, TCA cycle); some direct physical interactions within Complex I/V are known from structural biology but not demonstrated here

### 5. NT5E/CD73 — Immunosuppressive ectoenzyme
- **Direction**: Risk-associated; HR = 1.313, FDR = 0.039
- **Role**: Converts AMP to adenosine; immunosuppressive tumor microenvironment
- **Interactions**: Functional interaction with adenosine receptors (ADORA2A, not in cohort); literature documents CD73 as a prognostic biomarker across cancers (record 36480312)
- **Relationship type**: Pathway co-membership (adenosine signaling); indirect/putative relationship with immune cell infiltration

### 6. AKT3 — PI3K/AKT signaling
- **Direction**: Risk-associated; HR = 1.318, FDR = 0.039
- **Role**: Pro-survival kinase; downstream of growth factor receptors
- **Interactions**: Pathway co-membership with PI3K/AKT/mTOR signaling; regulatory interaction with GADD45B (stress response) is putative
- **Relationship type**: Pathway co-membership

### 7. MSLN — Mesothelin, tumor-associated antigen
- **Direction**: Risk-associated; HR = 1.313, FDR = 0.045
- **Role**: Cell-surface glycoprotein promoting adhesion/invasion; CAR-T target under evaluation in CRC organoids (record 42363170)
- **Interactions**: No clear interaction partners in this cohort; literature-based association with invasion
- **Relationship type**: Indirect/putative in this dataset

### 8. TPM4 — Actin cytoskeleton / EMT effector
- **Direction**: Risk-associated; HR = 1.364, FDR = 0.0089
- **Role**: Tropomyosin-4; stabilizes actin filaments in mesenchymal cells
- **Interactions**: Co-expression with EMT program; physical interaction with actin filaments (literature, not in dataset)
- **Relationship type**: Pathway co-membership (EMT/cytoskeletal remodeling)

### 9. SCARA3 — Scavenger receptor
- **Direction**: Risk-associated; HR = 1.377, FDR = 0.0024
- **Role**: Scavenger receptor implicated in oxidative stress response; less well-characterized in CRC
- **Interactions**: No clear interaction partners in this cohort
- **Relationship type**: Insufficient evidence for interaction claims

### 10. ABL2 — Non-receptor tyrosine kinase
- **Direction**: Risk-associated; HR = 1.301, FDR = 0.028
- **Role**: Kinase involved in cytoskeletal dynamics, invasion, and adhesion signaling
- **Interactions**: STRING records show interaction with CREBBP/EP300 networks (via MYB); functional interaction with actin cytoskeleton (literature)
- **Relationship type**: Pathway co-membership (kinase signaling, cytoskeletal regulation)

---

## 4. Validation Priorities

### Priority 1: EMT/Mesenchymal program as prognostic biomarker panel
- **Classification**: Biomarker
- **Why**: The EMT signature (ZEB1-AS1, TPM4, DCBLD2, ITGBL1) is coherent, multi-gene, and directionally consistent. EMT is mechanistically linked to metastasis and therapy resistance.
- **Current evidence**: Direct cohort statistics (HR > 1.3 for multiple genes, FDR < 0.05); no formal pathway enrichment P value computed
- **External evidence**: Strong literature support for ZEB1-AS1 and TPM4 in CRC aggressiveness; **external cohort validation was not performed**
- **Next step**: Test a composite EMT risk score in an independent CRC cohort (e.g., TCGA-COAD/READ) with survival endpoint; assess whether it adds to stage and MSI status
- **Conclusion status**: **Supported hypothesis**

### Priority 2: INHBB as mechanistic driver and potential therapeutic target
- **Classification**: Mechanistic hypothesis / Therapeutic target
- **Why**: INHBB has the strongest HR in the cohort and direct CRC-specific literature support; activin signaling is druggable
- **Current evidence**: HR = 1.433, FDR = 0.0011 (direct); literature records (41992239) show high INHBB in CRC drives malignant phenotypes
- **External evidence**: Europe PMC record 41992239 (independent CRC study); the drug-target existence (e.g., activin receptor inhibitors) does not constitute evidence of efficacy in CRC
- **Next step**: CRISPR knockout or shRNA knockdown of INHBB in CRC cell lines; assess effects on EMT markers, migration, and xenograft growth; test activin receptor inhibitors in INHBB-high models
- **Conclusion status**: **Supported hypothesis** (mechanistic role); **exploratory hypothesis** (therapeutic target in CRC)

### Priority 3: CDX2/CDX1 differentiation axis as protective biomarker
- **Classification**: Biomarker / Mechanistic hypothesis
- **Why**: CDX2 loss is a known poor-prognosis marker in CRC; the protective direction here is consistent and biologically coherent
- **Current evidence**: CDX2 HR = 0.748, CDX1 HR = 0.781 (direct); literature (30631044) shows CDX2 suppresses Wnt/β-catenin
- **External evidence**: Published CDX2 prognostic studies in CRC; **no new external cohort statistic supplied here**
- **Next step**: Immunohistochemistry for CDX2 protein in an independent CRC tissue microarray; correlate with OS and EMT markers; test whether CDX2 restoration reverses EMT in vitro
- **Conclusion status**: **Supported hypothesis** (biomarker); **established evidence** for CDX2's tumor-suppressive role in CRC (from prior literature, not from this dataset alone)

### Priority 4: Mitochondrial oxidative metabolism — composition check
- **Classification**: Confounding or composition check
- **Why**: The protective association of 8+ mitochondrial genes could reflect biological protection or simply higher tumor purity / lower stromal content in better-prognosis tumors
- **Current evidence**: Concordant protective HRs (0.686–0.758) across NDUFA9, ATP5B, ATP5G1, COA3, TIMM13, CS, ACSS2, OGDHL
- **External evidence**: Stromal tumors often show EMT and poor prognosis; mitochondrial genes are enriched in epithelial tumor cells
- **Next step**: Use ESTIMATE or xCell deconvolution to assess stromal/immune fractions; stratify by tumor purity; validate in microdissected tumor epithelium
- **Conclusion status**: **Exploratory hypothesis** — the protective association may be partly confounded by cell composition

### Priority 5: NT5E/CD73 immune modulation — interaction/network hypothesis
- **Classification**: Interaction / network hypothesis
- **Why**: CD73 is an established immunotherapy target; its risk association here (HR = 1.313) aligns with immunosuppressive adenosine signaling
- **Current evidence**: Direct cohort statistic (risk-associated); literature (36480312) supports CD73 as prognostic and immunotherapy-relevant across cancers
- **External evidence**: Anti-CD73 antibodies are in clinical trials (drug-target existence does not prove efficacy in CRC)
- **Next step**: Multiplex immunohistochemistry for CD73, CD8+ T cells, and FOXP3+ Tregs in CRC tumors; test whether CD73-high tumors show reduced CD8 infiltration and whether CD73 inhibition enhances anti-tumor immunity in CRC models
- **Conclusion status**: **Supported hypothesis** (prognostic association); **exploratory hypothesis** (therapeutic relevance in CRC)

---

## 5. Evidence Grounding Summary

| Program/Gene | Direct Cohort Statistic | Pathway/Ontology | Protein Interaction | Disease-Association Literature | Tissue/Expression | Therapeutic Evidence |
|---|---|---|---|---|---|---|
| EMT program (ZEB1-AS1, TPM4, DCBLD2) | Yes (HR > 1.3, FDR < 0.05) | Hallmark EMT (not formally tested) | STRING edges present | Yes (CRC literature) | GTEx/HPA records | Limited |
| INHBB | Yes (HR = 1.433, FDR = 0.0011) | TGF-β signaling (Reactome/KEGG) | Limited | Yes (Europe PMC 41992239) | HPA/GTEx | Activin receptor inhibitors exist (not CRC-proven) |
| CDX2/CDX1 | Yes (HR = 0.748/0.781) | Intestinal differentiation (GO) | Transcription factor networks (STRING: MYB-CREBBP/EP300) | Yes (Wnt suppression, 30631044) | HPA: intestinal epithelium | N/A |
| Mitochondrial module | Yes (8 genes, HR 0.686–0.758) | Oxidative phosphorylation (KEGG/Reactome) | STRING: COA3-ILVBL, CS-ACSS2 | Limited | GTEx: ubiquitous | N/A |
| NT5E/CD73 | Yes (HR = 1.313) | Adenosine signaling (Reactome) | Limited | Yes (36480312) | GTEx/HPA | Anti-CD73 in trials (not CRC-proven) |

**Independence caveat**: Literature records, pathway databases, and interaction databases may share underlying publications or prediction models. The INHBB literature record (41992239) and the CDX2 record (30631044) are independent studies but do not constitute validation of this specific cohort's statistics. **External statistical validation was not performed.**

---

## 6. Limitations and Alternative Explanations

### 1. Tissue composition / tumor purity
The protective mitochondrial signature and risk-associated EMT signature could partly reflect **tumor cell content versus stromal content**. EMT genes are often expressed by cancer-associated fibroblasts; mitochondrial genes by epithelial tumor cells. Tumors with high stromal content typically have worse prognosis — this could drive both signatures without a direct metabolic mechanism.
**How to address**: Deconvolution (ESTIMATE, xCell), laser-capture microdissection, or single-cell RNA-seq to determine cell-type-specific expression.

### 2. Disease stage and treatment exposure
OS is influenced by stage at diagnosis and treatment received. If the cohort is stage-heterogeneous, the HRs may partly reflect stage-associated biology rather than intrinsic aggressiveness. Treatment exposure (chemotherapy, radiation) was not included in the input.
**How to address**: Multivariable Cox models adjusting for stage, age, sex, and treatment; stratified analysis by stage.

### 3. Multiple probes and duplicate genes
53 duplicate genes/probes were retained (e.g., AKT3 has 7 rows, NIN has 5, ITGBL1 has 5). Some genes show **direction conflicts** across probes (DCBLD2, BCL2L14, LOC101928747|RBMX|SNORD61), which may indicate probe cross-hybridization or isoform-specific effects. The primary rows are deterministic representatives, but probe-level discrepancies warrant caution.
**How to address**: Validate with RNA-seq or qPCR for key genes; check probe annotation and genomic alignment.

### 4. Association-versus-causation ambiguity
All HRs are associations with OS, not causal relationships. INHBB, CDX2, and NT5E have mechanistic literature support, but the direction of causality (gene expression → survival vs. survival-related biology → expression) cannot be established from this dataset.
**How to address**: Functional perturbation experiments (knockdown/overexpression) in relevant models.

### 5. Batch/platform effects and cohort-specific bias
This appears to be a single microarray cohort. Platform-specific artifacts, batch effects, or population-specific genetic backgrounds could influence the results. The FDR control (71 genes at FDR ≤ 0.05) is reasonable, but the cohort may not generalize.
**How to address**: Independent cohort validation (TCGA, GSE39582, or other CRC expression cohorts) with explicit external statistics; meta-analysis across cohorts.

---

## Conclusion

This prognostic analysis of colorectal cancer identifies a coherent risk-associated signature of EMT/mesenchymal transition and TGF-β/activin signaling (led by INHBB, ZEB1-AS1, TPM4, DCBLD2, NT5E) alongside a protective-associated signature of intestinal differentiation (CDX2, CDX1) and mitochondrial oxidative metabolism (NDUFA9, ATP5B, ATP5G1, COA3, CS). The most defensible interpretation is that loss of differentiated intestinal identity with acquisition of mesenchymal and immunosuppressive phenotypes marks poor-prognosis CRC, while retained oxidative metabolism and antigen-presentation capacity mark better outcomes — but these conclusions are supported hypotheses requiring independent cohort validation, cell-composition adjustment, and functional perturbation experiments before any causal or therapeutic claims can be made.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=49, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: deepseek / deepseek-v4-flash.

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
